Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice

Jacek Jawien, Gabor Csanyi, Mariusz Gajda, Lukasz Mateuszuk, Magdalena Lomnicka, Ryszard Korbut, Stefan Chlopicki

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Platelets are involved in the development of atherothrombosis. However, the anti-atherosclerotic effects of thienopiridines have not been, as yet, proven. We analyzed the effects of ticlopidine on atherogenesis in apolipoprotein E/low density lipoprotein receptor double knockout (apoE/LDLR-/-) mice. 2-month-old apoE/LDLR-/- mice fed a Western diet (21% fat, 0.15% cholesterol) were treated with ticlopidine (90 mg/kg/day) for a period of 4 months. In 6-month-old apoE/LDLR-/- mice treated with ticlopidine and in their non-treated counterparts we analyzed: cholesterol and triglyceride levels, the size of atherosclerotic plaques in aortic roots (oil red-O staining, cross-section method), and in the whole aorta (Sudan IV staining, en face method), the number of macrophages in atherosclerotic plaque (CD68 staining), as well as the endothelial function in the isolated thoracic aorta. Concentrations of total cholesterol and triglycerides in plasma were not altered by treatment with ticlopidine. However, the size of atherosclerotic plaques measured in aortic roots by the cross-section method and the number of macrophages estimated by anti-CD68 staining were significantly reduced by ticlopidine treatment. In contrast, the effect of ticlopidine on the area covered by plaques in the whole aorta (en face analysis) was not statistically significant. Importantly, acetylcholine-induced vasodilation in isolated aorta was improved in ticlopidine-treated apoE/LDLR-/- mice as compared to their non-treated counterparts. In conclusion, ticlopidine attenuates the progression of atherosclerosis and improves the endothelial function in apoE/LDLR-/- mice.

Original languageEnglish (US)
Pages (from-to)129-135
Number of pages7
JournalEuropean Journal of Pharmacology
Volume556
Issue number1-3
DOIs
StatePublished - Feb 5 2007
Externally publishedYes

Fingerprint

Ticlopidine
LDL Receptors
Apolipoproteins E
Knockout Mice
Atherosclerosis
Atherosclerotic Plaques
Staining and Labeling
Aorta
Cholesterol
Triglycerides
Macrophages
Thoracic Aorta
Vasodilation
Acetylcholine
Blood Platelets
Fats

Keywords

  • ApoE/LDLR mice
  • Atherosclerosis
  • Endothelium
  • Ticlopidine

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. / Jawien, Jacek; Csanyi, Gabor; Gajda, Mariusz; Mateuszuk, Lukasz; Lomnicka, Magdalena; Korbut, Ryszard; Chlopicki, Stefan.

In: European Journal of Pharmacology, Vol. 556, No. 1-3, 05.02.2007, p. 129-135.

Research output: Contribution to journalArticle

Jawien, Jacek ; Csanyi, Gabor ; Gajda, Mariusz ; Mateuszuk, Lukasz ; Lomnicka, Magdalena ; Korbut, Ryszard ; Chlopicki, Stefan. / Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. In: European Journal of Pharmacology. 2007 ; Vol. 556, No. 1-3. pp. 129-135.
@article{0e6a02ccb697462d8d65998939ddcbe5,
title = "Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice",
abstract = "Platelets are involved in the development of atherothrombosis. However, the anti-atherosclerotic effects of thienopiridines have not been, as yet, proven. We analyzed the effects of ticlopidine on atherogenesis in apolipoprotein E/low density lipoprotein receptor double knockout (apoE/LDLR-/-) mice. 2-month-old apoE/LDLR-/- mice fed a Western diet (21{\%} fat, 0.15{\%} cholesterol) were treated with ticlopidine (90 mg/kg/day) for a period of 4 months. In 6-month-old apoE/LDLR-/- mice treated with ticlopidine and in their non-treated counterparts we analyzed: cholesterol and triglyceride levels, the size of atherosclerotic plaques in aortic roots (oil red-O staining, cross-section method), and in the whole aorta (Sudan IV staining, en face method), the number of macrophages in atherosclerotic plaque (CD68 staining), as well as the endothelial function in the isolated thoracic aorta. Concentrations of total cholesterol and triglycerides in plasma were not altered by treatment with ticlopidine. However, the size of atherosclerotic plaques measured in aortic roots by the cross-section method and the number of macrophages estimated by anti-CD68 staining were significantly reduced by ticlopidine treatment. In contrast, the effect of ticlopidine on the area covered by plaques in the whole aorta (en face analysis) was not statistically significant. Importantly, acetylcholine-induced vasodilation in isolated aorta was improved in ticlopidine-treated apoE/LDLR-/- mice as compared to their non-treated counterparts. In conclusion, ticlopidine attenuates the progression of atherosclerosis and improves the endothelial function in apoE/LDLR-/- mice.",
keywords = "ApoE/LDLR mice, Atherosclerosis, Endothelium, Ticlopidine",
author = "Jacek Jawien and Gabor Csanyi and Mariusz Gajda and Lukasz Mateuszuk and Magdalena Lomnicka and Ryszard Korbut and Stefan Chlopicki",
year = "2007",
month = "2",
day = "5",
doi = "10.1016/j.ejphar.2006.11.028",
language = "English (US)",
volume = "556",
pages = "129--135",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice

AU - Jawien, Jacek

AU - Csanyi, Gabor

AU - Gajda, Mariusz

AU - Mateuszuk, Lukasz

AU - Lomnicka, Magdalena

AU - Korbut, Ryszard

AU - Chlopicki, Stefan

PY - 2007/2/5

Y1 - 2007/2/5

N2 - Platelets are involved in the development of atherothrombosis. However, the anti-atherosclerotic effects of thienopiridines have not been, as yet, proven. We analyzed the effects of ticlopidine on atherogenesis in apolipoprotein E/low density lipoprotein receptor double knockout (apoE/LDLR-/-) mice. 2-month-old apoE/LDLR-/- mice fed a Western diet (21% fat, 0.15% cholesterol) were treated with ticlopidine (90 mg/kg/day) for a period of 4 months. In 6-month-old apoE/LDLR-/- mice treated with ticlopidine and in their non-treated counterparts we analyzed: cholesterol and triglyceride levels, the size of atherosclerotic plaques in aortic roots (oil red-O staining, cross-section method), and in the whole aorta (Sudan IV staining, en face method), the number of macrophages in atherosclerotic plaque (CD68 staining), as well as the endothelial function in the isolated thoracic aorta. Concentrations of total cholesterol and triglycerides in plasma were not altered by treatment with ticlopidine. However, the size of atherosclerotic plaques measured in aortic roots by the cross-section method and the number of macrophages estimated by anti-CD68 staining were significantly reduced by ticlopidine treatment. In contrast, the effect of ticlopidine on the area covered by plaques in the whole aorta (en face analysis) was not statistically significant. Importantly, acetylcholine-induced vasodilation in isolated aorta was improved in ticlopidine-treated apoE/LDLR-/- mice as compared to their non-treated counterparts. In conclusion, ticlopidine attenuates the progression of atherosclerosis and improves the endothelial function in apoE/LDLR-/- mice.

AB - Platelets are involved in the development of atherothrombosis. However, the anti-atherosclerotic effects of thienopiridines have not been, as yet, proven. We analyzed the effects of ticlopidine on atherogenesis in apolipoprotein E/low density lipoprotein receptor double knockout (apoE/LDLR-/-) mice. 2-month-old apoE/LDLR-/- mice fed a Western diet (21% fat, 0.15% cholesterol) were treated with ticlopidine (90 mg/kg/day) for a period of 4 months. In 6-month-old apoE/LDLR-/- mice treated with ticlopidine and in their non-treated counterparts we analyzed: cholesterol and triglyceride levels, the size of atherosclerotic plaques in aortic roots (oil red-O staining, cross-section method), and in the whole aorta (Sudan IV staining, en face method), the number of macrophages in atherosclerotic plaque (CD68 staining), as well as the endothelial function in the isolated thoracic aorta. Concentrations of total cholesterol and triglycerides in plasma were not altered by treatment with ticlopidine. However, the size of atherosclerotic plaques measured in aortic roots by the cross-section method and the number of macrophages estimated by anti-CD68 staining were significantly reduced by ticlopidine treatment. In contrast, the effect of ticlopidine on the area covered by plaques in the whole aorta (en face analysis) was not statistically significant. Importantly, acetylcholine-induced vasodilation in isolated aorta was improved in ticlopidine-treated apoE/LDLR-/- mice as compared to their non-treated counterparts. In conclusion, ticlopidine attenuates the progression of atherosclerosis and improves the endothelial function in apoE/LDLR-/- mice.

KW - ApoE/LDLR mice

KW - Atherosclerosis

KW - Endothelium

KW - Ticlopidine

UR - http://www.scopus.com/inward/record.url?scp=33846117498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846117498&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2006.11.028

DO - 10.1016/j.ejphar.2006.11.028

M3 - Article

C2 - 17174298

AN - SCOPUS:33846117498

VL - 556

SP - 129

EP - 135

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -